Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation
Hepatosplenic T-cell lymphoma is a very difficult lymphoma to deal with, almost impossible to cure. “Tandem” consolidation therapy with auto- stem cell transplant and allo- stem cell transplant can induce a long-lasting response and potentially cure this disease. (Source: Chemotherapy)
Source: Chemotherapy - May 10, 2022 Category: Cancer & Oncology Source Type: research

Examining the combination of cefixime and amoxicillin/clavulanate against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates
Conclusion: This study found that AMC improves the activity of CFM against ESBL E. coli and that this antibiotic combination has potential as an oral therapeutic option to treat ESBL E. coli UTIs. (Source: Chemotherapy)
Source: Chemotherapy - May 2, 2022 Category: Cancer & Oncology Source Type: research

Patients with Non-Muscle Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Gu érin Intravesical Instillation Therapy
Conclusion Patients with subsequent NMIBC after RNU treated with BCG intravesical instillation therapy have a higher risk of recurrence than those with primary NMIBC. Thus, stringent follow-up is necessary for patients with subsequent N MIBC after RNU. (Source: Chemotherapy)
Source: Chemotherapy - April 7, 2022 Category: Cancer & Oncology Source Type: research

The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine – a Case Report
A combination of azacitidine and venetoclax (AZA-VEN) has been approved for the treatment of adult treatment-na ïve acute myeloid leukemia (AML) patients, ineligible for intensive chemotherapy. The protocol may also constitute an alternative for the treatment of patients with mixed phenotype acute leukemia (MPAL), for which no established treatment guidelines exist. It may be anticipated, that alike in AML o r chronic lymphocytic leukemia, the treatment of MPAL may be complicated by the tumor lysis syndrome (TLS). No case of TLS in MPAL after venetoclax has been however reported so far. Here we present a case of a patient...
Source: Chemotherapy - March 24, 2022 Category: Cancer & Oncology Source Type: research

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma
Conclusions: Most patients with HGNEC received small-cell lung cancer-based regimens as postoperative adjuvant chemotherapy. Those who relapsed after adjuvant chemotherapy were mainly treated with amrubicin. Our findings suggest that platinum-doublet chemotherapy tends to improve the time to progression disease and overall survival in patients who relapse after postoperative adjuvant chemotherapy. (Source: Chemotherapy)
Source: Chemotherapy - March 21, 2022 Category: Cancer & Oncology Source Type: research

Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases
B/myeloid mixed-phenotype acute leukemia (MPAL) is an uncommon and aggressive leukemia without well-established treatment guidelines and has an inferior outcome. Relapsed/refractory (R/R) acute myeloid leukemia (AML) that is ineligible for aggressive chemotherapy regimens and allogeneic hematopoietic stem-cell transplantation has an extremely poor prognosis. The novel regimen of venetoclax (VEN) combined with hypomethylating agents (HMAs) has a synergistic therapeutic effect and a tolerable safety profile, which has been officially approved by the US Food and Drug Administration (FDA) for newly diagnosed AML in adults who ...
Source: Chemotherapy - March 18, 2022 Category: Cancer & Oncology Source Type: research

Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group
Conclusions: Our data from clinical practice showed that rituximab and chemotherapy is still an effective method of FL treatment resulting in survival more than 8 years from diagnosis in most patients. RCVP protocol followed with RM is a reasonable choice for the first-line therapy especially in low/intermediate group of patients. The prognosis was significantly worse in patients with POD24. Therefore, searching for precise initial clinical and biological markers is warranted and development therapies to improve prognosis of POD24 patients.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - March 4, 2022 Category: Cancer & Oncology Source Type: research

Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma - Real World Report of Polish Lymphoma Research Group
Conclusions: Our data from clinical practice showed that rituximab and chemotherapy is still an effective method of FL treatment resulting in s urvival more than 8 years from diagnosis in most patients. RCVP protocol followed with RM is a reasonable choice for the first-line therapy especially in low/intermediate group of patients. The prognosis was significantly worse in patients with POD24. Therefore, searching for precise initial clinica l and biological markers is warranted and development therapies to improve prognosis of POD24 patients. (Source: Chemotherapy)
Source: Chemotherapy - March 4, 2022 Category: Cancer & Oncology Source Type: research

Quercetin Inhibits Glioblastoma Growth and Prolongs Survival Rate through Inhibiting Glycolytic Metabolism
Conclusion: Mechanistically, quercetin inhibited proliferation and angiogenesis, promoted cancer cell apoptosis, and finally improved locomotor activity and survival by inhibiting the glycolytic metabolism in GBM tissues, suggesting that quercetin is a potential drug for the treatment of GBM. (Source: Chemotherapy)
Source: Chemotherapy - March 4, 2022 Category: Cancer & Oncology Source Type: research

Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-analysis of 22 randomized controlled trials
CONCLUSIONS: Compared with chemotherapy, PD-1/PD-L1 inhibitor monotherapy may cause more treatment-related pneumonitis. Increasing the dose of PD-1/PD-L1 inhibitor does not significantly increase the incidence of pneumonitis. Compared with the monotherapy, combination therapy does not increase the incidence of pneumonitis significantly. (Source: Chemotherapy)
Source: Chemotherapy - March 4, 2022 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of Super-Selective Bronchial Arterial Infusion Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
The objective response rate (ORR) and disease control rate (DCR) of NSCLC patients treated with SBAI were significantly higher than those of the control group (p (Source: Chemotherapy)
Source: Chemotherapy - February 8, 2022 Category: Cancer & Oncology Source Type: research

Body Mass Index of Elderly Patients with Normal Renal Function as a Determining Factor for Initial Vancomycin Regimen Designing
Introduction: Currently, the use of actual body weight is recommended for dosing in vancomycin regimen designs and it is important to perform therapeutic drug monitoring for efficacy and safety. However, the method to determine the appropriate vancomycin regimen for underweight or obese patients remains controversial. The aim of this study was to evaluate the impact of body mass index (BMI) on the relationship among vancomycin doses, trough concentration, and area under the curve (AUC). In addition, we identified the group of patients who were potentially more affected by BMI and evaluated the optimal dosing regimen to ach...
Source: Chemotherapy - February 8, 2022 Category: Cancer & Oncology Source Type: research

miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1
Conclusion: The findings showed that the interaction between BTZ, miR-466, and CCND1 determined the antitumor effect of BTZ on NSCLC.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - January 18, 2022 Category: Cancer & Oncology Source Type: research

The Effect of High CDC6 Levels on Predicting Poor Prognosis in Colorectal Cancer
Conclusion: CDC6 is highly expressed in CRC, and downregulation of CDC6 can slow the growth of CRC cells in vitro. It is also an independent predictor for poor prognosis and may be a useful biomarker for targeted therapy and prognostic evaluation.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - January 14, 2022 Category: Cancer & Oncology Source Type: research

Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1 < sup > mut < /sup > -AML Who Has Become Ineligible for High-Dose Consolidation
We report the case of a young patient with NPM1mut-AML who underwent a first cycle of intensive induction treatment, achieving a complete remission, but suffered from a serious life-threatening neurologic toxicity. Due to the ineligibility to further lines of intensive chemotherapy, we decided to consolidate the response with azacitidine, administered according to the regular schedule. The minimal residual disease (MRD), monitored through the NPM1 mutation at diagnosis, progressively decreased and became undetectable after 36 cycles of hypomethylating therapy. After 1 year from discontinuation of azacitidine, MRD remains u...
Source: Chemotherapy - January 12, 2022 Category: Cancer & Oncology Source Type: research